Galunisertib was effective in mouse pancreatic cancer models in inhibiting TGF-β1-mediated EMT and cancer cell migration, and inhibiting pSMAD2/3 induced proliferation of stromal fibroblasts. Here, TGFB1 is linked to cancer.